Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation - Greco, Claudia; Vitelli, Gaetano; Vercillo, Giuseppe; Vona, Rosa; Giannarelli, Diana; Sperduti, Isabella; Pisani, Francesco; Capoluongo, Ettore; Petti, Maria Concetta; Ameglio, Franco (Journal of experimental & clinical cancer research, 2009)
Keywords: Aged; Antineoplastic Agents, Alkylating - therapeutic use; Apoptosis; Biomedical and Life Sciences; Biomedicine; Cancer Research; Case-Control Studies; Female; Fibroblast Growth Factor 2 - blood; Fibroblast Growth Factor 2 - genetics; Genes, ras; Humans; Immunology; Insulin-like growth factor 1; Insulin-Like Growth Factor I - genetics; Insulin-Like Growth Factor I - metabolism; Male; Melphalan - therapeutic use; Middle Aged; Monoclonal gammopathies; Multiple myeloma; Multiple Myeloma - blood; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Mutation; Oncology; Paraproteinemias - blood; Paraproteinemias - drug therapy; Paraproteinemias - genetics; Physiological aspects; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - blood; Vascular Endothelial Growth Factor A - genetics; Italy; Vascular Endothelial Growth Factor; Plasma Cell Dyscrasia; Healthy Blood Donor; Serum bFGF; Multiple Myeloma